Record as secretary of state. What does she want to run on . What is the platform . She is going to be the first woman president. Ask for your support because i am a woman, though i am proud to be one. But i will force Hillary Clinton to fight on ground where she will have to talk about the reality that every one of her policies are bad for women as well as men. Fight on the to ground of her track record and if she faces me, we will win. [applause] i think that is a perfect conclusion to our day. Happy hanukkah ladies and gentlemen. Happy 30th anniversary. On the roadkes you to the white house and into the classroom. Our student cam documentary contest asks to tell us the issues they want to hear from president ial candidates. Our camthe details on contest at cspan. Org. I am here to voice my support for the courageous people of afghanistan. Women and man who has suffered for years under the taliban regime. Each of us has the responsibility to stop the suffering caused by malaria. Ever
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c
Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.
Tiziana Life Sciences Ltd.: Study Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
06.09.2023 - The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal . Seite 1